

Catalog# BP-50547

Efalizumab Biosimilar, CD11a Monoclonal Antibody

Efalizumab Biosimilar uses the same protein sequences as the therapeutic antibody efalizumab. Efalizumab is a monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis. Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. Efalizumab binds to CD11a, a subunit of leukocyte function antigen-1 (LFA-1), which is expressed on all leukocytes. As a result, efalizumab decreases cell surface expression of CD11a.

Product Details	
CAS No.	214745-43-4
Species Reactivity	Human
Source	Mammalian cells
Isotype	Human IgG1 kappa
Class	Monoclonal
Type	Antibody
Clone	Efalizumab Biosimilar
Conjugate	Unconjugated
Immunogen	Human CD11a
Purity	>95%
Molecular Weight	146.14 kDa
Protein Concentration	1 mg/ml
Formulation	0.2 µM filtered PBS solution, pH 6.0
Storage conditions	4°C for short time, -20°C or -80°C for long time.